Background: Studies have shown increased intestinal permeability in irritable bowel syndrome. Validating serum biomarkers for altered intestinal permeability in irritable bowel syndrome will facilitate research and pathophysiology-based therapy. Objective: To measure serum zonulin and intestinal fatty acid binding protein levels in diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome and compare with healthy controls and celiac disease. Methods: Serum zonulin and intestinal fatty acid binding protein levels were measured using enzyme-linked immunosorbent assays in constipation-predominant irritable bowel syndrome (n = 50), diarrhea-predominant irritable bowel syndrome (n = 50), celiac disease (n = 53) and healthy controls (n = 42). Irritable bowel syndrome symptom severity was measured using the irritable bowel syndrome-symptom severity scale. Results: Patients with constipation-predominant irritable bowel syndrome and diarrhea-predominant irritable bowel syndrome had higher zonulin levels compared with healthy controls (p = 0.006 and 0.009 respectively), which was comparable to those with active celiac disease. Although zonulin levels did not correlate with the overall irritable bowel syndrome symptom severity scale, it positively correlated with stool frequency per week (p = 0.03) and dissatisfaction with bowel habits (p = 0.007) in diarrhea-predominant irritable bowel syndrome. Patients with diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome had lower intestinal fatty acid binding protein levels compared with celiac patients (p = 0.005 and p = 0.047 respectively). Conclusion: Serum zonulin is upregulated in irritable bowel syndrome and the levels are comparable to those in celiac disease. Zonulin levels correlated with severity of bowel habits in diarrhea-predominant irritable bowel syndrome. Intestinal fatty acid binding protein levels in irritable bowel syndrome patients were not increased suggesting no significant increase in enterocyte death.
Background: Studies have shown increased intestinal permeability in irritable bowel syndrome. Validating serum biomarkers for altered intestinal permeability in irritable bowel syndrome will facilitate research and pathophysiology-based therapy. Objective: To measure serum zonulin and intestinal fatty acid binding protein levels in diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome and compare with healthy controls and celiac disease. Methods: Serum zonulin and intestinal fatty acid binding protein levels were measured using enzyme-linked immunosorbent assays in constipation-predominant irritable bowel syndrome (n = 50), diarrhea-predominant irritable bowel syndrome (n = 50), celiac disease (n = 53) and healthy controls (n = 42). Irritable bowel syndrome symptom severity was measured using the irritable bowel syndrome-symptom severity scale. Results:Patients with constipation-predominant irritable bowel syndrome and diarrhea-predominant irritable bowel syndrome had higher zonulin levels compared with healthy controls (p = 0.006 and 0.009 respectively), which was comparable to those with active celiac disease. Although zonulin levels did not correlate with the overall irritable bowel syndrome symptom severity scale, it positively correlated with stool frequency per week (p = 0.03) and dissatisfaction with bowel habits (p = 0.007) in diarrhea-predominant irritable bowel syndrome. Patients with diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome had lower intestinal fatty acid binding protein levels compared with celiac patients (p = 0.005 and p = 0.047 respectively). Conclusion: Serum zonulin is upregulated in irritable bowel syndrome and the levels are comparable to those in celiac disease. Zonulin levels correlated with severity of bowel habits in diarrhea-predominant irritable bowel syndrome. Intestinal fatty acid binding protein levels in irritable bowel syndromepatients were not increased suggesting no significant increase in enterocyte death.
Entities:
Keywords:
Intestinal permeability; gut barrier; serine protease; tight junction
Authors: Archana S Rao; Michael Camilleri; Deborah J Eckert; Irene Busciglio; Duane D Burton; Michael Ryks; Banny S Wong; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-08-11 Impact factor: 4.052
Authors: E Smecuol; J C Bai; H Vazquez; Z Kogan; A Cabanne; S Niveloni; S Pedreira; L Boerr; E Mauriño; J B Meddings Journal: Gastroenterology Date: 1997-04 Impact factor: 22.682
Authors: Krisztina Gecse; Richárd Róka; Teréz Séra; András Rosztóczy; Anita Annaházi; Ferenc Izbéki; Ferenc Nagy; Tamás Molnár; Zoltán Szepes; László Pávics; Lionel Bueno; Tibor Wittmann Journal: Digestion Date: 2011-12-14 Impact factor: 3.216
Authors: Maria I Vazquez-Roque; Michael Camilleri; Thomas Smyrk; Joseph A Murray; Eric Marietta; Jessica O'Neill; Paula Carlson; Jesse Lamsam; Denise Janzow; Deborah Eckert; Duane Burton; Alan R Zinsmeister Journal: Gastroenterology Date: 2013-01-25 Impact factor: 22.682
Authors: Hirsh D Komarow; Jason M Brenchley; Andrea Robin Eisch; Michael L Young; Linda M Scott; Joseph M Kulinski; Theo Heller; Yun Bai; Dean D Metcalfe Journal: Clin Exp Allergy Date: 2020-12-10 Impact factor: 5.401
Authors: Gian Paolo Caviglia; Alessandra Tucci; Rinaldo Pellicano; Sharmila Fagoonee; Chiara Rosso; Maria Lorena Abate; Antonella Olivero; Angelo Armandi; Ester Vanni; Giorgio Maria Saracco; Elisabetta Bugianesi; Marco Astegiano; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-07-23 Impact factor: 4.241
Authors: Enid E Martinez; David Zurakowski; Luis Pereira; Rachel Freire; John B Emans; Samuel Nurko; Christopher P Duggan; Alessio Fasano; Nilesh M Mehta Journal: JPEN J Parenter Enteral Nutr Date: 2020-06-03 Impact factor: 4.016
Authors: Aaron J Riviere; Kristen S Smith; Megan N Schaberg; Michael W Greene; Andrew D Frugé Journal: BMC Gastroenterol Date: 2022-04-12 Impact factor: 3.067
Authors: Gian Paolo Caviglia; Chiara Rosso; Francesco Stalla; Martina Rizzo; Alessandro Massano; Maria Lorena Abate; Antonella Olivero; Angelo Armandi; Ester Vanni; Ramy Younes; Sharmila Fagoonee; Rinaldo Pellicano; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-03-15 Impact factor: 4.241